Gastrointestinal distress can manifest in an array of symptoms, including abdominal pain, bloating, diarrhea, constipation, and reflux. For many, these symptoms can be debilitating, affecting daily activities, food choices, and overall quality of life. According to a recent survey, 61% of Americans reported experiencing at least one GI symptom in the past week, and diagnoses such as irritable bowel syndrome (IBS) are common, affecting an estimated 6.1% of adults. Despite how common gastrointestinal symptoms are, many people struggle to find lasting relief. Among patients on prescribed therapy for GI conditions, more than half report dissatisfaction, highlighting a clear need for approaches that go beyond symptom management to address the root cause.
While musculoskeletal pain and gastrointestinal distress are often treated as separate conditions, emerging research suggests the two may be more closely connected than previously thought. Dysbiosis, an imbalance in the gut microbiota, has been shown to influence musculoskeletal health by compromising intestinal barrier integrity, promoting immune activation, and driving systemic inflammation. One dietary factor that may contribute to this process is gluten. In non-celiac gluten-sensitive individuals, the gliadin protein can increase intestinal permeability, triggering immune activation that can extend beyond the gut. While these symptoms are frequently treated as separate conditions, they may share a common cause, driven by disruptions occurring primarily in the gut.
A recent case report examined the effects of a personalized nutrition and nutraceutical protocol in a 35-year-old female with a longstanding history of gastrointestinal and systemic symptoms, including bloating, altered bowel function, fatigue, cognitive complaints, and progressive musculoskeletal discomfort. Despite trying various dietary modifications, chiropractic care, and over-the-counter supplements, she experienced little lasting relief. A comprehensive stool analysis revealed digestive insufficiency, altered microbial balance, and markers of intestinal barrier disruption, including elevated zonulin and increased anti-gliadin IgA, an immune response to gliadin in the intestines. Baseline symptom burden was assessed using the Medical Symptom Questionnaire (MSQ) and the Gastrointestinal Symptom Rating Scale (GSRS). At baseline, her total MSQ score was 75, while GSRS domain scores were elevated across multiple categories, including indigestion (4.0), diarrhea (3.6), and constipation (3.0). The patient was subsequently placed on a targeted intervention consisting of dietary modification and nutraceutical support over approximately ten weeks.
A targeted nutraceutical protocol was implemented, alongside a gluten-free diet, given the patient's elevated anti-gliadin IgA. The protocol included demulcents such as deglycyrrhizinated licorice (DGL), aloe vera extract, slippery elm, marshmallow root, okra extract, and chamomile extract; mucosal support nutrients including L-glutamine, zinc from zinc L-carnosine, N-acetyl-D-glucosamine, citrus pectin, and mucin; ingredients to support healthy inflammatory responses such as quercetin, cat's claw, methylsulfonylmethane (MSM), and omega-3 fatty acids (EPA and DHA) from fish oil; a multi-strain probiotic blend containing Lactobacillus and Bifidobacterium species; a butyrate postbiotic in the form of tributyrin; a resistant starch and fiber blend including green banana flour and arabinogalactan; and a topical cannabidiol (CBD) cream for localized musculoskeletal support.
Following the intervention, the patient was reassessed at approximately five and ten weeks. The results were notable across both measures. Total MSQ score improved from 75 at baseline to 31 at the five-week mark, a 58.7% reduction in overall symptom burden, and declined further to 13 by the final assessment, representing an 82.7% improvement from baseline. Improvements were observed in several categories, including the digestive tract, joints and muscles, weight, energy and activity, and cognitive symptoms. GSRS scores followed a similar pattern, with diarrhea symptoms improving by 55.6%, indigestion by 43.8%, and abdominal pain by 23.1% at the final follow-up.
Within the first two weeks of starting the protocol, the patient reported that facial puffiness had resolved, bloating had subsided, joint pain had disappeared, and her energy had improved. By the final assessment, she described waking up early without an alarm and feeling refreshed, representing a meaningful shift from where she had started. No adverse effects were reported throughout the intervention.
The findings from this case highlight the interconnected nature of gastrointestinal and musculoskeletal health. While causality cannot be established in a single case report, the rate and extent of improvement suggest that intestinal barrier dysfunction and microbial imbalance likely contributed to ongoing immune activation beyond the gut. Eliminating gluten, given the patient’s elevated anti-gliadin IgA and zonulin levels, likely reduced a key driver of intestinal permeability and downstream immune activation. The nutraceutical protocol, targeting microbial balance, barrier integrity, and inflammatory signaling, may have further supported this process by improving the gut environment and reducing immune stimulation. When combined, this approach appears to have addressed underlying dysfunction rather than merely managing individual symptoms, likely contributing to the broader improvements observed across several systems.
This case illustrates the value of a more holistic approach when navigating overlapping gastrointestinal and musculoskeletal symptoms. By using functional stool testing to guide a personalized dietary and nutraceutical protocol, meaningful improvements were observed across a wide range of symptom domains in a relatively short period of time. As with any single case report, these findings reflect an individual response and may not be generalizable. Further research is needed to better understand how gut-directed interventions may influence musculoskeletal outcomes across broader populations, and to clarify the contribution of individual components within personalized protocols.
Learn more about gut and joint health:
Osteoarthritis and the Gut Microbiome: Is There a Link?
Meta-analysis Investigates Omega-3 PUFAs and Age-Related Changes to Joint Health
By Jesse Martin, MS
Designs for Health has been dedicated to being the most trusted source for superior quality, science-based nutritional products for nearly three decades. We’re committed to maximizing successful health outcomes by providing healthcare practitioners with comprehensive support through our extensive product line, ongoing clinical education, and practice development programs. The blogs we publish here cover a range of topics, including new and original approaches to diet and healthcare, analyses of the latest cutting-edge research, deep-dives into specific nutrients, botanicals, nutraceuticals and more, all fully referenced for those who want to dig deeper into the primary literature.
